Not yet recruitingPriority 4 · Lower priorityNCT07657572

A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.

Plain-language summary

This trial is studying a new treatment for people with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

Age 18 Years or older
See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length: Ask the trial team for details
Visit frequency: Ask the trial team for details

TrialCompass — Clinical Trial Summary

A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.

NCT07657572

Phase: | Status: Not yet recruiting | Priority: Lower

Plain-language summary

This trial is studying a new treatment for people with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

Age 18 Years or older
See full trial listing for complete eligibility

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 1000 patients

Primary endpoint: Progression-free survival

Ages: 18 Years to —

Start date: 2026-06 | Est. completion: 2030-12

Locations

0 US sites · 0 total

Contact

Weili Zhao | zwl_trial@163.com | 086-022-64370045

Sponsor: Ruijin Hospital (OTHER)

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07657572

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.